S&P 500
5,921.54
+2.0%
+$118.72
DJI
42,343.65
+1.8%
+$740.58
NASDAQ
19,199.16
+2.5%
+$461.96
Bitcoin
108,800.00
-0.3%
-288.94
AAPL
$200.00
+2.4%
+$4.73
AMZN
$205.78
+2.4%
+$4.79
GOOG
$173.90
+2.5%
+$4.32
META
$641.62
+2.3%
+$14.56
MSFT
$460.09
+2.2%
+$9.91
NVDA
$135.32
+3.1%
+$4.03
TSLA
$361.87
+6.6%
+$22.53
Sagimet Biosciences (NASDAQ: SGMT)
$3.37
(-2.3%)
-$0.08
Price as of May 27, 2025, 3:56 p.m. ET
Sagimet Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Sagimet Biosciences Company Info
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.